4//SEC Filing
CADENCE PHARMACEUTICALS INC 4
Accession 0001209191-14-022402
CIK 0001333248operating
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 1:46 PM ET
Size
5.9 KB
Accession
0001209191-14-022402
Insider Transaction Report
Form 4
Newman Stephen L
Director
Transactions
- Disposition to Issuer
stock option (right to buy)
2014-03-19$8.60/sh−37,500$322,500→ 0 totalExercise: $5.40Exp: 2023-03-13→ common stock (37,500 underlying)
Footnotes (1)
- [F1]In connection with the merger of Cadence Pharmaceuticals, Inc. ("Cadence") with Madison Merger Sub, Inc. ("Merger Sub") on March 19, 2014, and pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") by and among Cadence, Mallinckrodt plc ("Parent") and Merger Sub, dated February 10, 2014, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (a) the number of shares of common stock of Cadence underlying such option multiplied by (b) the excess, if any, of $14.00 (the "Offer Price") over the exercise price per share of such option.
Documents
Issuer
CADENCE PHARMACEUTICALS INC
CIK 0001333248
Entity typeoperating
Related Parties
1- filerCIK 0001333248
Filing Metadata
- Form type
- 4
- Filed
- Mar 20, 8:00 PM ET
- Accepted
- Mar 21, 1:46 PM ET
- Size
- 5.9 KB